VERIFIEDET Finance·8 May 2026neutral

Biocon shifts focus to margins, capacity utilisation after expansion phase

AI Summary

·Biocon is prioritizing capacity utilization and margin expansion after global investments.
·The company reported a 13% revenue increase for FY26, but net profit declined.
·Biocon is exploring in-licensing for its biosimilars and focusing on profitable growth.